Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 147

1.

The glutathione redox system is essential to prevent ferroptosis caused by impaired lipid metabolism in clear cell renal cell carcinoma.

Miess H, Dankworth B, Gouw AM, Rosenfeldt M, Schmitz W, Jiang M, Saunders B, Howell M, Downward J, Felsher DW, Peck B, Schulze A.

Oncogene. 2018 Jun 5. doi: 10.1038/s41388-018-0315-z. [Epub ahead of print]

PMID:
29872221
2.

The MYC oncogene is a global regulator of the immune response.

Casey SC, Baylot V, Felsher DW.

Blood. 2018 May 3;131(18):2007-2015. doi: 10.1182/blood-2017-11-742577. Epub 2018 Mar 7. Review.

PMID:
29514782
3.

Anti-miR-17 therapy delays tumorigenesis in MYC-driven hepatocellular carcinoma (HCC).

Dhanasekaran R, Gabay-Ryan M, Baylot V, Lai I, Mosley A, Huang X, Zabludoff S, Li J, Kaimal V, Karmali P, Felsher DW.

Oncotarget. 2017 Nov 9;9(5):5517-5528. doi: 10.18632/oncotarget.22342. eCollection 2018 Jan 19.

4.

DNMT3B overexpression contributes to aberrant DNA methylation and MYC-driven tumor maintenance in T-ALL and Burkitt's lymphoma.

Poole CJ, Zheng W, Lodh A, Yevtodiyenko A, Liefwalker D, Li H, Felsher DW, van Riggelen J.

Oncotarget. 2017 Aug 10;8(44):76898-76920. doi: 10.18632/oncotarget.20176. eCollection 2017 Sep 29.

5.

Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression.

Hebb JPO, Mosley AR, Vences-Catalán F, Rajasekaran N, Rosén A, Ellmark P, Felsher DW.

Cancer Immunol Immunother. 2018 Jan;67(1):47-60. doi: 10.1007/s00262-017-2059-y. Epub 2017 Sep 13.

PMID:
28905118
6.

MYC activation cooperates with Vhl and Ink4a/Arf loss to induce clear cell renal cell carcinoma.

Bailey ST, Smith AM, Kardos J, Wobker SE, Wilson HL, Krishnan B, Saito R, Lee HJ, Zhang J, Eaton SC, Williams LA, Manocha U, Peters DJ, Pan X, Carroll TJ, Felsher DW, Walter V, Zhang Q, Parker JS, Yeh JJ, Moffitt RA, Leung JY, Kim WY.

Nat Commun. 2017 Jun 8;8:15770. doi: 10.1038/ncomms15770.

7.

Corrigendum to "KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study" [Leuk. Res. 50 (Nov) (2016) 123-131. PubMed PMID: 27736729].

Swords RT, Greenberg PL, Wei AH, Durrant S, Advani AS, Hertzberg MS, Lewis ID, Rivera G, Gratzinger D, Fan AC, Felsher DW, Cortes JE, Watts JM, Yarranton GT, Walling JM, Lancet JE.

Leuk Res. 2017 Aug;59:65. doi: 10.1016/j.leukres.2017.02.007. Epub 2017 May 30. No abstract available.

PMID:
28575698
8.

Oncogene KRAS activates fatty acid synthase, resulting in specific ERK and lipid signatures associated with lung adenocarcinoma.

Gouw AM, Eberlin LS, Margulis K, Sullivan DK, Toal GG, Tong L, Zare RN, Felsher DW.

Proc Natl Acad Sci U S A. 2017 Apr 25;114(17):4300-4305. doi: 10.1073/pnas.1617709114. Epub 2017 Apr 11.

9.

MYC: Master Regulator of Immune Privilege.

Casey SC, Baylot V, Felsher DW.

Trends Immunol. 2017 Apr;38(4):298-305. doi: 10.1016/j.it.2017.01.002. Epub 2017 Feb 21. Review.

10.

KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study.

Swords RT, Greenberg PL, Wei AH, Durrant S, Advani AS, Hertzberg MS, Jonas BA, Lewis ID, Rivera G, Gratzinger D, Fan AC, Felsher DW, Cortes JE, Watts JM, Yarranton GT, Walling JM, Lancet JE.

Leuk Res. 2016 Nov;50:123-131. doi: 10.1016/j.leukres.2016.09.012. Epub 2016 Sep 28. Erratum in: Leuk Res. 2017 Aug;59:65.

PMID:
27736729
11.

BIM-mediated apoptosis and oncogene addiction.

Li Y, Deutzmann A, Felsher DW.

Aging (Albany NY). 2016 Sep 29;8(9):1834-1835. doi: 10.18632/aging.101072. No abstract available.

12.

Affordable Cancer Medications Are Within Reach but We Need a Different Approach.

Felsher DW, Lowe L.

J Clin Oncol. 2016 Jun 20;34(18):2194-5. doi: 10.1200/JCO.2016.67.2436. Epub 2016 May 9. No abstract available.

PMID:
27161965
13.

BIM mediates oncogene inactivation-induced apoptosis in multiple transgenic mouse models of acute lymphoblastic leukemia.

Li Y, Deutzmann A, Choi PS, Fan AC, Felsher DW.

Oncotarget. 2016 May 10;7(19):26926-34. doi: 10.18632/oncotarget.8731.

14.

MYC regulates the antitumor immune response through CD47 and PD-L1.

Casey SC, Tong L, Li Y, Do R, Walz S, Fitzgerald KN, Gouw AM, Baylot V, Gütgemann I, Eilers M, Felsher DW.

Science. 2016 Apr 8;352(6282):227-31. doi: 10.1126/science.aac9935. Epub 2016 Mar 10. Erratum in: Science. 2016 Apr 8;352(6282). pii: aaf7984. doi: 10.1126/science.aaf7984.

15.

NAFLD causes selective CD4(+) T lymphocyte loss and promotes hepatocarcinogenesis.

Ma C, Kesarwala AH, Eggert T, Medina-Echeverz J, Kleiner DE, Jin P, Stroncek DF, Terabe M, Kapoor V, ElGindi M, Han M, Thornton AM, Zhang H, Egger M, Luo J, Felsher DW, McVicar DW, Weber A, Heikenwalder M, Greten TF.

Nature. 2016 Mar 10;531(7593):253-7. doi: 10.1038/nature16969. Epub 2016 Mar 2.

16.

Metabolic vulnerabilities of MYC-induced cancer.

Gouw AM, Toal GG, Felsher DW.

Oncotarget. 2016 May 24;7(21):29879-80. doi: 10.18632/oncotarget.7223. No abstract available.

17.

Designing a broad-spectrum integrative approach for cancer prevention and treatment.

Block KI, Gyllenhaal C, Lowe L, Amedei A, Amin ARMR, Amin A, Aquilano K, Arbiser J, Arreola A, Arzumanyan A, Ashraf SS, Azmi AS, Benencia F, Bhakta D, Bilsland A, Bishayee A, Blain SW, Block PB, Boosani CS, Carey TE, Carnero A, Carotenuto M, Casey SC, Chakrabarti M, Chaturvedi R, Chen GZ, Chen H, Chen S, Chen YC, Choi BK, Ciriolo MR, Coley HM, Collins AR, Connell M, Crawford S, Curran CS, Dabrosin C, Damia G, Dasgupta S, DeBerardinis RJ, Decker WK, Dhawan P, Diehl AME, Dong JT, Dou QP, Drew JE, Elkord E, El-Rayes B, Feitelson MA, Felsher DW, Ferguson LR, Fimognari C, Firestone GL, Frezza C, Fujii H, Fuster MM, Generali D, Georgakilas AG, Gieseler F, Gilbertson M, Green MF, Grue B, Guha G, Halicka D, Helferich WG, Heneberg P, Hentosh P, Hirschey MD, Hofseth LJ, Holcombe RF, Honoki K, Hsu HY, Huang GS, Jensen LD, Jiang WG, Jones LW, Karpowicz PA, Keith WN, Kerkar SP, Khan GN, Khatami M, Ko YH, Kucuk O, Kulathinal RJ, Kumar NB, Kwon BS, Le A, Lea MA, Lee HY, Lichtor T, Lin LT, Locasale JW, Lokeshwar BL, Longo VD, Lyssiotis CA, MacKenzie KL, Malhotra M, Marino M, Martinez-Chantar ML, Matheu A, Maxwell C, McDonnell E, Meeker AK, Mehrmohamadi M, Mehta K, Michelotti GA, Mohammad RM, Mohammed SI, Morre DJ, Muralidhar V, Muqbil I, Murphy MP, Nagaraju GP, Nahta R, Niccolai E, Nowsheen S, Panis C, Pantano F, Parslow VR, Pawelec G, Pedersen PL, Poore B, Poudyal D, Prakash S, Prince M, Raffaghello L, Rathmell JC, Rathmell WK, Ray SK, Reichrath J, Rezazadeh S, Ribatti D, Ricciardiello L, Robey RB, Rodier F, Rupasinghe HPV, Russo GL, Ryan EP, Samadi AK, Sanchez-Garcia I, Sanders AJ, Santini D, Sarkar M, Sasada T, Saxena NK, Shackelford RE, Shantha Kumara HMC, Sharma D, Shin DM, Sidransky D, Siegelin MD, Signori E, Singh N, Sivanand S, Sliva D, Smythe C, Spagnuolo C, Stafforini DM, Stagg J, Subbarayan PR, Sundin T, Talib WH, Thompson SK, Tran PT, Ungefroren H, Vander Heiden MG, Venkateswaran V, Vinay DS, Vlachostergios PJ, Wang Z, Wellen KE, Whelan RL, Yang ES, Yang H, Yang X, Yaswen P, Yedjou C, Yin X, Zhu J, Zollo M.

Semin Cancer Biol. 2015 Dec;35 Suppl:S276-S304. doi: 10.1016/j.semcancer.2015.09.007. Review.

18.

ARF: connecting senescence and innate immunity for clearance.

Kearney AY, Anchang B, Plevritis S, Felsher DW.

Aging (Albany NY). 2015 Sep;7(9):613-5.

19.

MYC Disrupts the Circadian Clock and Metabolism in Cancer Cells.

Altman BJ, Hsieh AL, Sengupta A, Krishnanaiah SY, Stine ZE, Walton ZE, Gouw AM, Venkataraman A, Li B, Goraksha-Hicks P, Diskin SJ, Bellovin DI, Simon MC, Rathmell JC, Lazar MA, Maris JM, Felsher DW, Hogenesch JB, Weljie AM, Dang CV.

Cell Metab. 2015 Dec 1;22(6):1009-19. doi: 10.1016/j.cmet.2015.09.003. Epub 2015 Sep 17.

20.

Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead.

Goodson WH 3rd, Lowe L, Carpenter DO, Gilbertson M, Manaf Ali A, Lopez de Cerain Salsamendi A, Lasfar A, Carnero A, Azqueta A, Amedei A, Charles AK, Collins AR, Ward A, Salzberg AC, Colacci A, Olsen AK, Berg A, Barclay BJ, Zhou BP, Blanco-Aparicio C, Baglole CJ, Dong C, Mondello C, Hsu CW, Naus CC, Yedjou C, Curran CS, Laird DW, Koch DC, Carlin DJ, Felsher DW, Roy D, Brown DG, Ratovitski E, Ryan EP, Corsini E, Rojas E, Moon EY, Laconi E, Marongiu F, Al-Mulla F, Chiaradonna F, Darroudi F, Martin FL, Van Schooten FJ, Goldberg GS, Wagemaker G, Nangami GN, Calaf GM, Williams G, Wolf GT, Koppen G, Brunborg G, Lyerly HK, Krishnan H, Ab Hamid H, Yasaei H, Sone H, Kondoh H, Salem HK, Hsu HY, Park HH, Koturbash I, Miousse IR, Scovassi AI, Klaunig JE, Vondráček J, Raju J, Roman J, Wise JP Sr, Whitfield JR, Woodrick J, Christopher JA, Ochieng J, Martinez-Leal JF, Weisz J, Kravchenko J, Sun J, Prudhomme KR, Narayanan KB, Cohen-Solal KA, Moorwood K, Gonzalez L, Soucek L, Jian L, D'Abronzo LS, Lin LT, Li L, Gulliver L, McCawley LJ, Memeo L, Vermeulen L, Leyns L, Zhang L, Valverde M, Khatami M, Romano MF, Chapellier M, Williams MA, Wade M, Manjili MH, Lleonart ME, Xia M, Gonzalez MJ, Karamouzis MV, Kirsch-Volders M, Vaccari M, Kuemmerle NB, Singh N, Cruickshanks N, Kleinstreuer N, van Larebeke N, Ahmed N, Ogunkua O, Krishnakumar PK, Vadgama P, Marignani PA, Ghosh PM, Ostrosky-Wegman P, Thompson PA, Dent P, Heneberg P, Darbre P, Sing Leung P, Nangia-Makker P, Cheng QS, Robey RB, Al-Temaimi R, Roy R, Andrade-Vieira R, Sinha RK, Mehta R, Vento R, Di Fiore R, Ponce-Cusi R, Dornetshuber-Fleiss R, Nahta R, Castellino RC, Palorini R, Abd Hamid R, Langie SA, Eltom SE, Brooks SA, Ryeom S, Wise SS, Bay SN, Harris SA, Papagerakis S, Romano S, Pavanello S, Eriksson S, Forte S, Casey SC, Luanpitpong S, Lee TJ, Otsuki T, Chen T, Massfelder T, Sanderson T, Guarnieri T, Hultman T, Dormoy V, Odero-Marah V, Sabbisetti V, Maguer-Satta V, Rathmell WK, Engström W, Decker WK, Bisson WH, Rojanasakul Y, Luqmani Y, Chen Z, Hu Z.

Carcinogenesis. 2015 Jun;36 Suppl 1:S254-96. doi: 10.1093/carcin/bgv039. Review. Erratum in: Carcinogenesis. 2016 Mar;37(3):344.

21.

The effect of environmental chemicals on the tumor microenvironment.

Casey SC, Vaccari M, Al-Mulla F, Al-Temaimi R, Amedei A, Barcellos-Hoff MH, Brown DG, Chapellier M, Christopher J, Curran CS, Forte S, Hamid RA, Heneberg P, Koch DC, Krishnakumar PK, Laconi E, Maguer-Satta V, Marongiu F, Memeo L, Mondello C, Raju J, Roman J, Roy R, Ryan EP, Ryeom S, Salem HK, Scovassi AI, Singh N, Soucek L, Vermeulen L, Whitfield JR, Woodrick J, Colacci A, Bisson WH, Felsher DW.

Carcinogenesis. 2015 Jun;36 Suppl 1:S160-83. doi: 10.1093/carcin/bgv035. Review.

22.

MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism.

Shroff EH, Eberlin LS, Dang VM, Gouw AM, Gabay M, Adam SJ, Bellovin DI, Tran PT, Philbrick WM, Garcia-Ocana A, Casey SC, Li Y, Dang CV, Zare RN, Felsher DW.

Proc Natl Acad Sci U S A. 2015 May 26;112(21):6539-44. doi: 10.1073/pnas.1507228112. Epub 2015 May 11.

23.

Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis.

Xiang Y, Stine ZE, Xia J, Lu Y, O'Connor RS, Altman BJ, Hsieh AL, Gouw AM, Thomas AG, Gao P, Sun L, Song L, Yan B, Slusher BS, Zhuo J, Ooi LL, Lee CG, Mancuso A, McCallion AS, Le A, Milone MC, Rayport S, Felsher DW, Dang CV.

J Clin Invest. 2015 Jun;125(6):2293-306. doi: 10.1172/JCI75836. Epub 2015 Apr 27.

24.

Cancer prevention and therapy through the modulation of the tumor microenvironment.

Casey SC, Amedei A, Aquilano K, Azmi AS, Benencia F, Bhakta D, Bilsland AE, Boosani CS, Chen S, Ciriolo MR, Crawford S, Fujii H, Georgakilas AG, Guha G, Halicka D, Helferich WG, Heneberg P, Honoki K, Keith WN, Kerkar SP, Mohammed SI, Niccolai E, Nowsheen S, Vasantha Rupasinghe HP, Samadi A, Singh N, Talib WH, Venkateswaran V, Whelan RL, Yang X, Felsher DW.

Semin Cancer Biol. 2015 Dec;35 Suppl:S199-S223. doi: 10.1016/j.semcancer.2015.02.007. Epub 2015 Apr 10. Review.

25.

p19ARF is a critical mediator of both cellular senescence and an innate immune response associated with MYC inactivation in mouse model of acute leukemia.

Yetil A, Anchang B, Gouw AM, Adam SJ, Zabuawala T, Parameswaran R, van Riggelen J, Plevritis S, Felsher DW.

Oncotarget. 2015 Feb 28;6(6):3563-77.

26.

Oncogene addiction: resetting the safety switch?

Li Y, Choi PS, Felsher DW.

Oncotarget. 2014 Sep 30;5(18):7986-7. No abstract available.

27.

miR-17-92 explains MYC oncogene addiction.

Li Y, Casey SC, Choi PS, Felsher DW.

Mol Cell Oncol. 2014 Dec 31;1(4):e970092. doi: 10.4161/23723548.2014.970092. eCollection 2014 Oct-Dec.

28.

Activation of Cre recombinase alone can induce complete tumor regression.

Li Y, Choi PS, Casey SC, Felsher DW.

PLoS One. 2014 Sep 10;9(9):e107589. doi: 10.1371/journal.pone.0107589. eCollection 2014.

29.

MYC through miR-17-92 suppresses specific target genes to maintain survival, autonomous proliferation, and a neoplastic state.

Li Y, Choi PS, Casey SC, Dill DL, Felsher DW.

Cancer Cell. 2014 Aug 11;26(2):262-72. doi: 10.1016/j.ccr.2014.06.014.

30.

Oncogene withdrawal engages the immune system to induce sustained cancer regression.

Casey SC, Li Y, Fan AC, Felsher DW.

J Immunother Cancer. 2014 Jul 15;2:24. doi: 10.1186/2051-1426-2-24. eCollection 2014. Review.

31.

Addiction to multiple oncogenes can be exploited to prevent the emergence of therapeutic resistance.

Choi PS, Li Y, Felsher DW.

Proc Natl Acad Sci U S A. 2014 Aug 12;111(32):E3316-24. doi: 10.1073/pnas.1406123111. Epub 2014 Jul 28.

32.

Alteration of the lipid profile in lymphomas induced by MYC overexpression.

Eberlin LS, Gabay M, Fan AC, Gouw AM, Tibshirani RJ, Felsher DW, Zare RN.

Proc Natl Acad Sci U S A. 2014 Jul 22;111(29):10450-5. doi: 10.1073/pnas.1409778111. Epub 2014 Jul 3.

33.

MYC activation is a hallmark of cancer initiation and maintenance.

Gabay M, Li Y, Felsher DW.

Cold Spring Harb Perspect Med. 2014 Jun 2;4(6). pii: a014241. doi: 10.1101/cshperspect.a014241. Review.

34.

Bioorthogonal cyclization-mediated in situ self-assembly of small-molecule probes for imaging caspase activity in vivo.

Ye D, Shuhendler AJ, Cui L, Tong L, Tee SS, Tikhomirov G, Felsher DW, Rao J.

Nat Chem. 2014 Jun;6(6):519-26. doi: 10.1038/nchem.1920. Epub 2014 Apr 28.

35.

An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation.

Casey SC, Li Y, Felsher DW.

Immunol Res. 2014 May;58(2-3):282-91. doi: 10.1007/s12026-014-8503-6. Review.

36.

Angiocrine factors deployed by tumor vascular niche induce B cell lymphoma invasiveness and chemoresistance.

Cao Z, Ding BS, Guo P, Lee SB, Butler JM, Casey SC, Simons M, Tam W, Felsher DW, Shido K, Rafii A, Scandura JM, Rafii S.

Cancer Cell. 2014 Mar 17;25(3):350-65. doi: 10.1016/j.ccr.2014.02.005.

37.

Inactivation of MYC reverses tumorigenesis.

Li Y, Casey SC, Felsher DW.

J Intern Med. 2014 Jul;276(1):52-60. doi: 10.1111/joim.12237. Review.

38.

Metabolic changes in cancer cells upon suppression of MYC.

Anso E, Mullen AR, Felsher DW, Matés JM, Deberardinis RJ, Chandel NS.

Cancer Metab. 2013 Feb 4;1(1):7. doi: 10.1186/2049-3002-1-7.

39.

A tumor-immune mathematical model of CD4+ T helper cell dependent tumor regression by oncogene inactivation.

Nwabugwu CI, Rakhra K, Felsher DW, Paik DS.

Conf Proc IEEE Eng Med Biol Soc. 2013;2013:4529-32. doi: 10.1109/EMBC.2013.6610554.

40.

Development of novel tumor-targeted theranostic nanoparticles activated by membrane-type matrix metalloproteinases for combined cancer magnetic resonance imaging and therapy.

Ansari C, Tikhomirov GA, Hong SH, Falconer RA, Loadman PM, Gill JH, Castaneda R, Hazard FK, Tong L, Lenkov OD, Felsher DW, Rao J, Daldrup-Link HE.

Small. 2014 Feb 12;10(3):566-75, 417. doi: 10.1002/smll.201301456. Epub 2013 Aug 27.

41.

Generation of a tetracycline regulated mouse model of MYC-induced T-cell acute lymphoblastic leukemia.

Rakhra K, Felsher DW.

Methods Mol Biol. 2013;1012:221-35. doi: 10.1007/978-1-62703-429-6_15.

PMID:
24006068
42.

BCL-2 inhibition with ABT-737 prolongs survival in an NRAS/BCL-2 mouse model of AML by targeting primitive LSK and progenitor cells.

Beurlet S, Omidvar N, Gorombei P, Krief P, Le Pogam C, Setterblad N, de la Grange P, Leboeuf C, Janin A, Noguera ME, Hervatin F, Sarda-Mantel L, Konopleva M, Andreeff M, Tu AW, Fan AC, Felsher DW, Whetton A, Pla M, West R, Fenaux P, Chomienne C, Padua RA.

Blood. 2013 Oct 17;122(16):2864-76. doi: 10.1182/blood-2012-07-445635. Epub 2013 Aug 13.

43.

Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of cancer.

Fan AC, O'Rourke JJ, Praharaj DR, Felsher DW.

Expert Opin Investig Drugs. 2013 Nov;22(11):1495-509. doi: 10.1517/13543784.2013.829453. Epub 2013 Aug 12. Review.

44.

A c-Myc activation sensor-based high-throughput drug screening identifies an antineoplastic effect of nitazoxanide.

Fan-Minogue H, Bodapati S, Solow-Cordero D, Fan A, Paulmurugan R, Massoud TF, Felsher DW, Gambhir SS.

Mol Cancer Ther. 2013 Sep;12(9):1896-905. doi: 10.1158/1535-7163.MCT-12-1243. Epub 2013 Jul 3.

45.

Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma.

Kapanadze T, Gamrekelashvili J, Ma C, Chan C, Zhao F, Hewitt S, Zender L, Kapoor V, Felsher DW, Manns MP, Korangy F, Greten TF.

J Hepatol. 2013 Nov;59(5):1007-13. doi: 10.1016/j.jhep.2013.06.010. Epub 2013 Jun 22.

46.

In vivo imaging-based mathematical modeling techniques that enhance the understanding of oncogene addiction in relation to tumor growth.

Nwabugwu C, Rakhra K, Felsher D, Paik D.

Comput Math Methods Med. 2013;2013:802512. doi: 10.1155/2013/802512. Epub 2013 Mar 20.

47.

Noncanonical roles of the immune system in eliciting oncogene addiction.

Casey SC, Bellovin DI, Felsher DW.

Curr Opin Immunol. 2013 Apr;25(2):246-58. doi: 10.1016/j.coi.2013.02.003. Epub 2013 Apr 6. Review.

48.

Characterization of MYC-induced tumorigenesis by in situ lipid profiling.

Perry RH, Bellovin DI, Shroff EH, Ismail AI, Zabuawala T, Felsher DW, Zare RN.

Anal Chem. 2013 May 7;85(9):4259-62. doi: 10.1021/ac400479j. Epub 2013 Apr 18.

49.

Role of MYCN in retinoblastoma.

Felsher DW.

Lancet Oncol. 2013 Apr;14(4):270-1. doi: 10.1016/S1470-2045(13)70070-6. Epub 2013 Mar 13. No abstract available.

PMID:
23498720
50.

Dormant cancer cells contribute to residual disease in a model of reversible pancreatic cancer.

Lin WC, Rajbhandari N, Liu C, Sakamoto K, Zhang Q, Triplett AA, Batra SK, Opavsky R, Felsher DW, DiMaio DJ, Hollingsworth MA, Morris JP 4th, Hebrok M, Witkiewicz AK, Brody JR, Rui H, Wagner KU.

Cancer Res. 2013 Mar 15;73(6):1821-30. doi: 10.1158/0008-5472.CAN-12-2067. Epub 2013 Mar 6.

Supplemental Content

Loading ...
Support Center